Illumina, Inc. (ILMN) is a publicly traded company in the Healthcare sector, operating within the Medical - Diagnostics & Research industry. The company is headquartered in San Diego, CA, United States. The current CEO is Jacob Thaysen.
ILMN has IPO date of 2000-07-28, 8,970 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $19.93B.
Illumina, Inc. is a global leader in sequencing and array-based solutions for genetic and genomic analysis, founded in 1998 and headquartered in San Diego, California. The company develops and manufactures instruments and consumables for genetic analysis, along with genotyping, sequencing, and cancer detection testing services that enable genomic adoption across research, clinical, and commercial markets. Its products serve diverse applications including life sciences research, oncology, reproductive health, agriculture, and emerging segments, with customers spanning academic institutions, government laboratories, hospitals, pharmaceutical firms, biotechnology companies, and molecular diagnostic laboratories. Illumina distributes its offerings through direct sales channels in North America, Europe, Latin America, and the Asia-Pacific region, as well as through partnerships with life-science distributors across multiple international markets. The company generates revenue through instrument sales, consumable products, genotyping and sequencing services, instrument service contracts, and licensing agreements.
